Arbutus to present at jefferies london healthcare conference

Warminster, pa., nov. 08, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis b virus (chbv) infection, today announced that the arbutus management team will participate in and host one-on-one meetings at the following investor conference:
ABUS Ratings Summary
ABUS Quant Ranking